TriSalus Life Sciences announced its financial results for the fourth quarter and full year ended December 31, 2024. The company reported full year 2024 revenue of $29.4 million, representing a 59% growth year-over-year. Fourth quarter 2024 revenue was $8.261 million, an increase of 44% compared to Q4 2023.
Operating Cash Flow in the fourth quarter of 2024 was ($5.7) million, showing an improvement from ($10.8) million in the previous quarter. Cash and Cash Equivalents stood at $8.5 million as of December 31, 2024. The company reaffirmed its 2025 guidance, expecting greater than 50% revenue growth, over 20% reduction in operating expenses, positive full year EBITDA, and positive cash flow in the second half of 2025.
However, TriSalus also announced it would file a Form 12b-25, Notification of Late Filing, with the SEC for its 2024 Annual Report on Form 10-K. This delay is primarily due to identified errors in determining stock-based compensation and clinical trial related research and development expense timing in 2024, with the company diligently evaluating the materiality of these errors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.